derived. In this report I describe this approach and its application using several examples previously Interpatient variability in drug disposition and rereported by us and others. sponse is a therapeutic premise, and thus evaluation and management of such variability are the basis for individualized pharmacotherapy. If the math-
INTRODUCTION ematical approach to determining drug doses were accurate and practical, the use of calculated doses
Pharmacokinetic studies are important for optimizing could reduce the potential for toxicity and decrease drug therapy. They are essential to dosage dethe need for repetitious drug assays. The major termination, efficacy studies and toxicology studies. strength of the population pharmacokinetics apPharmacokinetic studies may generally be categorized proach is that useful information can be extracted into two types: (a) population-based investigations, from sparse data collected during routine clinical (b) individual-based investigations. The former studies care. Population pharmacokinetics can be defined as pool samples from more than one subject to obtain the study of the variability in serum drug conthe pharmacokinetic estimates, while the latter studies centrations between individuals when standard dosdevelop estimates from each individual subject using a age regimens are administered. An approach to sequence of samples. The major strength of population population pharmacokinetic data analysis has been pharmacokinetics is that useful information can be implemented in the Nonlinear Mixed Effects Model extracted from sparse data collected during routine (nonmem) computer program. This report shows the clinical care. Population pharmacokinetics can be defeasibility of using a simple pharmacokinetic screen fined as the study of the variability in serum drug approach to estimate the population mean relative concentrations between individuals when standard drug clearance and detecting drug-drug interaction dosage regimens are administered. It is of interest both by use of nonmem. In clinical application of multiple to measure this variability within the population and trough screen or multiple peak screen, the variability to account for it in terms of patient variables, such of drug relative clearance within the population is as age, body weight, gender, disease state or drug assessed and a mathematical relationship between interaction with concomitant drug. One major aim drug relative clearance and individual patient charof these studies has been to establish guidelines for acteristics, such as age, body weight, gender, disease adjustment of dosage regimens to be used together state or drug interaction with concomitant drug is with Therapeutic Drug Monitoring and a Bayesian feedback algorithm. Sheiner & Benet (1) have provided an excellent summary of various population ap-examined the feasibility of using the multiple trough (ii) Nonlinear model: CL= 1 ×factor 1 2 approach or multiple peak approach for pharmacokinetic screening of the effects of patient variables where the factors are continuous variables such as on the population estimates of a drug's relative clearage or body weight, and 1 , . . . , k are the parameters ance. A method of population pharmacokinetic data to be estimated. analysis has been implemented in the Nonlinear Mixed Effects Model (nonmem) computer program, de-(iii)
Step model: CL= 1 veloped by Beal & Sheiner (2).
If factor present, CL= 1 × 2 factor where factor is a discrete variable such as female gender.
THEORY
The following models were used to describe the intersubject variability in clearance: Multiple trough screen or multiple peak screen
In this design, an attempt is made to obtain more than CL ij =C L ij (1+ j ) Proportional model one steady-state trough (or peak) concentration from each patient. Although single trough (or peak) data where CL ij is the ith true clearance for the jth inneed not be discarded, two or more trough (or peak) dividual, C L ij is the ith clearance predicted for the jth values obtained on separate occasions will allow the individual with the regression model, and j is an variance components to be estimated. These screenings independently distributed random variable with mean provide a reasonable approach to the assessment of zero and variances CL 2 . pharmacokinetic variability in a large, heterogeneous
Residual variability on the concentration was modpatient population. However, this approach for pharelled in two ways: macokinetic screening is more qualitative than quantitative, and cannot be expected to provide reliable Css ij =C ss ij + ij Additive model quantification of the magnitude of pathophysiological effects due to uncertainties in the data (e.g. compliance,
Css ij =C ss ij (1+ ij ) Proportional model timing) and pharmacokinetic model misspecification.
where Css ij is the ith measured steady-state serum concentration in the jth patient, C ss ij is the corPharmacokinetic model to estimate drug relative responding predicted steady-state serum conclearance centration, and ij is the residual intrasubject variability term, representing independent identically distributed The pharmacokinetics of a drug can be described by statistical error with mean zero and variance E 2 . the following steady-state pharmacokinetic model:
Data analysis
where D ij is the dosage of drug for the ith Css in the In the data studies undertaken by us, data analysis jth patient; Css ij is the steady-state serum concentration was performed with nonmem (2) (Version III, level 1·2 measured in the jth patient while he or she received or Version IV, level 1·1) on the Kyushu University the ith dosage; CL ij is the ith total body clearance in computer (FACOM M-1800) or the Hewlett Packard the jth patient; and ij is the dosing interval for the ith computer (HP Apollo 9000 model 712/60). dosage in the jth patient. A bioavailability (F) of unity Minimizing the objective function provided by each is assumed for this model; if it is not, CL ij must be nonmem fitting routine is equivalent to maximizing regarded as (CL/F) ij .
the likelihood of the data. Hypothesis testing can be Clinical factors were then included in the model performed by monitoring changes in the objective according to the following general approaches: function when one or more parameters in the model are first estimated iteratively and then restricting each to a fixed value. The difference in the values of the (i) Linear model: CL= 1 + 2 ×factor 1+ 3 ×factor 2 objective function is asymptotically distributed beregimen for individual patients. nonmem estimates using the multiple trough approach suggest that this tween two competitive models according to the chisquare distribution with degree of freedom equal to digoxin's clearance is influenced by the age (years), total body weight (kg), serum creatinine (mg/dL), the difference in the number of parameters between the two models.
gender, the coadministration of spilonolactone, the presence or absence of congestive heart failure and The first stage in the model-building phase is to use a minimum number of parameters that are thought to the dose (7). influence clearance. Alternative statistical models are then tested to determine which model would afford CL (L/day)=106·0×(1-0·00475×age)× the best fit of the data. Additional parameters can be body weight 0·310 × Serum creatinine The retention of serum creatinine in the model for model includes all parameters that cannot be elimdrug clearance supports the view that the principal inated from the full regression model during this elimination of digoxin takes place via renal excretion. restriction process.
Digoxin clearance increases non-linearly with an increasing total body weight. The inclusion of age in the model also indicates that an elderly patient is expected to have a lower clearance than a young patient of
CLINICAL APPLICATION
equal body weight and serum creatinine. The clearance in females was on average 14·2% less than in males.
Drug relative clearance using steady-state trough
There is a great deal of similarity with the differences concentrations measured before the morning oral between males and females obtained using the predose diction formulae of creatinine clearance proposed by Jelliffe (8) and Cockroft & Gault (9), and which were Digoxin 10 and 15%, respectively.
Using the approach adopted in this study, the effects Digoxin is a cardiac glycoside that is widely prescribed for the treatment of congestive heart failure and atrial on bioavailability and clearance cannot be separated, as only their ratio (CL/F) was estimated. The oral fibrillation. It is well known that digoxin is a difficult drug to dose because of a lack of a good relationship bioavailability of digoxin, although somewhat variable, has been reported to be ≈70% from tablets between the dose and the desired effect, its narrow therapeutic range reported to be 0·5-2·0 ng/ml, and (4). The bioavailability of orally administered digoxin tablets in healthy volunteers has been shown to be the variation in the pharmacokinetic characteristics of the drug (3). Knowledge of the pharmacokinetics of dose-independent over the range of doses of one to eight tablets (10). However, the regression model for digoxin is essential in optimizing the safety and efficacy of this drug (4, 5). The variability in this drug's clearance suggests that clearance increases by about 20% with an increase in dose from half a tablet to one clearance creates difficulty for the clinician in choosing the drug dosage. For a given daily dosage, steadytablet as the daily dose of digoxin. The decreased clearance with the half tablet dosage may reflect state serum digoxin concentrations vary greatly from patient to patient (6). Because of this large interpatient changes in bioavailability or renal and non-renal excretion activity, or both. variability, the clinician needs an appropriate dosage The clearance of digoxin decreased by about 10% clearance creates difficulty for the clinician in choosing the correct dosage. The pharmacokinetics of digitalis with spironolactone administration, an effect which is comparable to values previously reported for renal glycosides were studied using routine therapeutic drug monitoring data to evaluate the role of patient clearance of digoxin in earlier sutdies (24%, 18%, 13% and 12·2%, respectively) (11) (12) (13) (14) . The effects of gender characteristics for estimating metildigoxin dosing regimens. nonmem estimates using the multiple trough and spironolactone on glycoside clearance were also observed in patients who received metildigoxin (15) .
approach indicated that the clearance of this digitalis glycoside was influenced by the subject's age (years), This effect may reflect decreased renal excretion due to inhibition of p-glycoprotein transport of digoxin by total body weight (kg), serum creatinine (mg/dL), gender, daily dose ( g/kg/day) and the cospironolactone (16), or cross reactivity with the assay antibody used in the FPIA method, due to the strucadministration of spilonolactone as shown in the following formulae (15) . tural similarity between spironolactone metabolites and digoxin (17) or both.
Several investigators found that congestive heart CL (L/day)=(13·4-0·0589×age)× failure was an important factor in estimating digoxin body weight
× clearance (18, 19) . Sheiner et al. (18) found that the daily dose 0·163 ×0·89 GEN-SPI digoxin clearance was significantly lower in patients GEN-SPI=1 for female or combination of spiwith congestive heart failure than in patients without ronolactone congestive heart failure [clearance (L/h)= 0·06×creatinine clearance (ml/min)+0·05×body GEN-SPI=0 for otherwise weight (kg) for without congestive heart failure; clear-
The effects of gender and spironolactone adance (L/h)=0·053×creatinine clearance (ml/ ministration on clearance cannot be separated (logmin)+0·02×body weight (kg) for with congestive likelihood difference of 2·391, P> 0·05). Despite the heart failure]. Naafs et al. (19) found that digoxin's confounding, the effect of gender on clearance appears clearance was significantly lower in patients with conto be similar to that reported in a previous digoxin gestive heart failure than in patients with atrial fibstudy (7). This effect of spironolactone administration rillation (2·88±1·26 vs. 4·26±2·16 L/h). In this study, may reflect decreased renal and nonrenal elimination digoxin clearance decreased by about 19% in the pres-(11), or cross-reactivity with the assay antibody (17) ence of congestive heart failure.
or both. Using the approach used in this study, the effects Metildigoxin on bioavailavility and clearance cannot be separated, as only their ratio (CL/F) is estimated. The final reMetildigoxin is designed to reduce the polarity of gression model for clearance suggests that the rate of digoxin and to enhance intestinal absorption by subclearance increases nonlinearly with increasing daily stituting a methyl group for the hydroxyl group on dose of metildigoxin. This factor was significant with the tridigitoxose residue of digoxin (3, 6). It has positive a log-likelihood difference of 7·083 (P< 0·01), but was inotropic effects equal to digoxin (20, 21) slowing heart of minor significance with a 95% confidence interval rate in patients with atrial fibrillation (22) . It is virtually value which included zero. It is not known if the completely absorbed with an absorption rate of more increased clearance at higher dosages is caused by than 90% (23) , and its elimination half-life is about the changes in bioavailavility or renal and nonrenal exsame as that of digoxin (24) . Metildigoxin is first cretion activity, or both. metabolized to digoxin and then hydrolysed to the sugar residue-free metabolites; digoxigenin bisdigitoxoside, digoxigenin monodigotoxoside and diLithium goxigenin. After a single oral administration of metildigoxin, about 55% of the dose is excreted in Lithium is the primary treatment for long-term prophylaxis of recurrent bipolar (manic-depressive) disurine over 156 h as metildigoxin (53·7%) and digoxin (42·6%) (25) . Knowledge of the pharmacokinetics of orders and for short-term treatment of mania. The efficacy and toxicity of lithium in patients with bipolar metildigoxin is essential in optimizing the safety and efficacy of this drug. The variability in this drug's disorder are claimed to be closely related to serum lithium concentration, with the therapeutic range repharmacokinetic studies in a large group of paediatric patients. Until our recent publication of a large popuported to be 0·6-1·2 mEq/L (26, 27). The therapeutic range for lithium was established based on conlation study from Japanese patients, comprising both adults and children (43) , pharmacokinetic information centrations drawn 12 h after the dosage, regardless of the dosing interval. The narrow therapeutic range and for phenobarbital in epileptic patients has been limited (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) . the large intersubject differences in lithium disposition (28, 29) have led to the development of several dosing
There are several important findings in this retrospective analysis of effects of the maturation process strategies (30-38) . The large degree of variability observed in lithium pharmacokinetics makes it difficult and drug-drug interaction on phenobarbital clearance (43) . First, nonmem analysis suggests that total body to predict a priori the optimal dosing regimen for an individual subject. nonmem estimates using the weight was superior to age as an index of the maturation process. Second, phenobarbital clearance was multiple trough approach suggest that lithium clearance was influenced by the demographic variables age highest in the very young and decreased in a weightrelated fashion in children (0·4-14 years), with minimal (years), total body weight (kg), and serum creatinine (mg/dL) (39) .
changes observed in adults (15-33·4 years). This pattern was consistent whether phenobarbital was administered alone or coadministered with other CL (L/day)=31·6-0·634× (age-50) × antiepileptic drugs. Third, when phenobarbital was H+(-7·79+0·225×body weight)/serum creatinine coadministered with other antiepileptic drugs, phenobarbital clearance decreased as compared with that H=0 for age <50 in monotherapy.
H=1 for age ≥50
In South African children, the (final) model describing clearance included total body weight, the Jermain et al. (40) suggested that lean body weight parameter which was also the most important fixed showed that concomitant administration of pheclearance was 1·5 L/h with a coefficient of variation nobarbital and carbamazepine resulted in a 15% deof 38%, and was found to increase with body weight. crease on phenobarbital clearance for children. Botha et al. (54) showed that concomitant administration of phenobarbital and carbamazepine or phenytoin resulted in a 13% decrease on phenobarbital clearance Drug relative clearance using steady-state for South African children.
concentrations measured at any time after
The effects of drug-drug interaction on phemorning oral dose nobarbital clearance were examined through a retrospective analysis of serum concentration data from Phenobarbital 349 paediatric and adult epileptic patients (age range, 0·4-33·3 years) (57). Patients received phenobarbital Phenobarbital is the oldest, and one of the most widely as monotherapy or in combination with either the used of the modern antiepileptic drugs. It has been antiepileptic drugs carbamazepine or valproic acid. suggested that the therapeutic serum concentration The final regression model for clearance using nonrange for this drug is 10-40 g/ml in epileptic seizures mem was: (42) . Optimal use of phenobarbital in paediatric patients requires information regarding the drug's pharmacokinetics. However, because of sampling restrictions, it is often difficult to perform traditional CL (ml/kg/hr)=52·3×body weight bamazepine clearance decreases nonlinearly with The mechanism by which valproic acid causes pheincreasing total body weight in the maturation process. nobarbital accumulation is thought to involve inTotal body weight was superior to age as an index of hibition of phenobarbital metabolism (58) . Subsequent the maturation process (an age range of 5 months to clinical trials confirmed that serum phenobarbital 15 years) in nonmem analysis. One possible exlevels rose when valproic acid therapy was initiated.
planation proposed for those findings is that younger The increases usually have ranged from 15% to 70%, children may have a higher metabolic capacity for but at times have been much higher (59). Botha et al.
carbamazepine. (54) showed that concomitant administration of pheThe final regression model suggests that carnobarbital and valproic acid resulted in a 38% decrease bamazepine clearance increases nonlinearly with inon phenobarbital clearance for South African children.
creasing daily dose of carbamazepine. It is not known Using our approach, concomitant administration of if the increased carbamazepine clearance at higher phenobarbital and valproic acid resulted in a 35·8% dosages is caused by changes in bioavailability, hepatic decrease on phenobarbital clearance. enzyme activity, or both. However, absorption of carbamazepine from the gastrointestinal tract is slow and extremely variable. It is most plausible that the Carbamazepine fractional absorption of carbamazepine decreases with higher doses because of its low aqueous solubility Carbamazepine is currently considered the drug of choice for the treatment of partial seizures, generalized and the limiting effects of dissolution on the rate of absorption (74) . tonic-clonic seizures, and other minor or partial seizure disorders. Carbamazepine is also approved as the drug
In the approach adopted, the effects on bioavailability and clearance cannot be separated, as only of choice for treatment of the pain associated with trigeminal neuralgia. It is well known that cartheir ratio (CL/F) is estimated. A further complicating factor is the question of whether the increase in carbamazepine is a difficult drug to dose because of a lack of a good relationship between dose and desired bamazepine clearance with increasing dose is in fact due to an increased clearance in younger children effect, its narrow therapeutic range reported to be 4-12 g/ml in epileptic seizures, and the variation in or to a decrease in drug absorption. However, the improvement in fit obtained with the inclusions of the pharmacokinetic characteristics of the drug (60, 61). It has become apparent that the variation in total body weight and carbamazepine dose indicates that it may be due to incomplete or very slow disthe pharmacokinetics of carbamazepine is affected primarily by age (62-65), dose (65-67) and comsolution of high doses of carbamazepine in the gastrointestinal fluid. edication (68) (69) (70) (71) (72) . The concomitant use of enzymeinducing antiepileptics such as phenytoin, phe-
The following model describing carbamazepine clearance in Portuguese epileptic children included nobarbital and primidone decreases average serum carbamazepine concentrations. There are a number of total body weight and carbamazepine dose, the parameters which were also the important fixed effect conflicting reports on the effect of valproic acid on carbamazepine disposition. Thus, evaluation and manparameters, as well as age ([CL (L/h)=(0·0122×body weight (kg)+0·0467×daily dose (mg/kg/day))×age agement of such variability form the basis for optimizing therapy at the level of the individual.
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] for carbamazepine monotherapy) (75) .
Several studies have noted the induction of carhas a broad spectrum of activity against both the convulsive and nonconvulsive generalized epilepsies. bamazepine clearance by the concomitant administration of other antiepileptic drugs (68) (69) (70) (71) (72) . Drug It has been suggested that the therapeutic serum concentration range for this drug is 50-100 g/ml in epiinteractions with carbamazepine include its increased enzymatic biotransformation by phenobarbital, phenleptic seizures (76) . Optimal use of valproic acid in ytoin and primidone. Valproic acid increases the unpaediatric patients requires information regarding the bound fractions of both carbamazepine and drug's pharmacokinetics. carbamazepine epoxide and inhibits the metabolism Valproic acid is often administered with other antiof the latter through hepatic microsomal epoxide epileptic drugs, a practice that can lead to clinically hydrolase. Using the present approach, concomitant significant pharmacologic interactions. Concomitant administration of carbamazepine and valproic acid administration of such enzyme-inducing antiepileptic led to an increase in carbamazepine clearance of 7%.
drugs as carbamazepine, phenobarbital, primidone or However, there are a number of conflicting reports on phenytoin will markedly accelerate the metabolic conthe effect of valproic acid on carbamazepine disversion of valproic acid, particularly in children (77-position. Both increases and decreases in car-82). bamazepine concentrations have been observed
The effects of drug-drug interaction on valproic following the addition of valproic acid (71) . In addition, acid clearance were examined through a retrospective elevation of carbamazepine epoxide concentration has analysis of serum concentration data from paediatric been reported after the addition of valproic acid (74) .
and adult epileptic patients (83) . Patients received Since the interaction between valproic acid and carvalproic acid as monotherapy or in combination with bamazepine may involve both displacements from either the antiepileptic drugs carbamazepine or pheprotein binding and metabolic inhibition, carnobarbital. The final regression model for clearance bamazepine concentrations may increase, decrease, or by nonmem was: remain unchanged where the drugs are coadministered, depending on which effect prevails. The CL (ml/kg/h)=15·6×body weight (kg) (90) found that the concentration of valproic acid was lower when the drug was given drawal of associated antiepileptic drugs may change antiepileptic drug dosage requirements. Therefore, in combination with phenobarbital (76·3%) than when given alone (100%). A similar effect has been noted routine monitoring of antiepileptic drug serum levels would be extremely useful, especially in the paediatric with carbamazepine (66·2%). Carbamazepine has been reported to increase the metabolic clearance and deage group, and in patients requiring associated antiepileptic medication. crease the plasma concentration of valproic acid (81, 82, 91, 92) . The specific metabolic pathways induced by This simple pharmacokinetic screen represents a reasonable approach to the assessment of pharcarbamazepine include glucuronidation, oxidation, and -1 oxidation (93). Using the present approach, macokinetic variability in a large, heterogeneous patient population. However, it should be kept in mind the concomitant administration of carbamazepine led to induction of clearance of valproic acid higher than that this approach is more qualitative than quantitative and may not be expected to provide reliable quanis seen with phenobarbital.
Clinically important drug interactions between valtification of the magnitude of pathophysiologic effects due to pharmacokinetic model mis-specification. proic acid and carbamazepine or phenobarbital may occur not only when one drug is added but also when it is withdrawn from therapy. Withdrawal of carbamazepine or phenobarbital alters valproic acid REFERENCES concentrations to a lesser degree, the average increase being 50% and 67%, respectively (94). For example, weight, gender, disease state or drug interaction with
